6.14
price up icon16.07%   0.85
 
loading
Schlusskurs vom Vortag:
$5.29
Offen:
$5.3
24-Stunden-Volumen:
6.75M
Relative Volume:
2.97
Marktkapitalisierung:
$337.39M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.4939
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
+18.99%
1M Leistung:
+42.79%
6M Leistung:
+3.72%
1J Leistung:
+106.73%
1-Tages-Spanne:
Value
$5.15
$6.29
1-Wochen-Bereich:
Value
$4.86
$6.29
52-Wochen-Spanne:
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
Firmenname
Verastem Inc
Name
Telefon
(781) 292-4200
Name
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Name
Mitarbeiter
78
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
VSTM's Discussions on Twitter

Vergleichen Sie VSTM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VSTM
Verastem Inc
6.14 290.68M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Eingeleitet Jefferies Buy
2025-03-24 Bestätigt H.C. Wainwright Buy
2024-12-31 Bestätigt BTIG Research Buy
2024-09-30 Eingeleitet Guggenheim Buy
2023-11-21 Fortgesetzt BTIG Research Buy
2023-09-27 Eingeleitet B. Riley Securities Buy
2023-06-15 Hochstufung Mizuho Neutral → Buy
2022-09-07 Fortgesetzt Alliance Global Partners Buy
2022-04-29 Fortgesetzt Cantor Fitzgerald Overweight
2022-04-14 Eingeleitet RBC Capital Mkts Outperform
2022-03-09 Eingeleitet Truist Buy
2021-07-01 Eingeleitet Alliance Global Partners Buy
2021-05-24 Hochstufung BTIG Research Neutral → Buy
2019-06-20 Herabstufung BTIG Research Buy → Neutral
2019-05-10 Herabstufung Raymond James Outperform → Mkt Perform
2018-07-13 Eingeleitet BTIG Research Buy
2018-05-02 Eingeleitet Seaport Global Securities Buy
2018-03-08 Eingeleitet B. Riley FBR, Inc. Buy
2017-09-07 Bestätigt H.C. Wainwright Buy
2017-04-13 Eingeleitet Oppenheimer Outperform
2017-03-24 Bestätigt H.C. Wainwright Buy
2015-09-29 Herabstufung Cantor Fitzgerald Buy → Hold
2015-09-29 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 Herabstufung Jefferies Buy → Hold
2015-09-29 Herabstufung Raymond James Strong Buy → Outperform
2015-09-28 Herabstufung Mizuho Buy → Neutral
2015-09-28 Herabstufung ROTH Capital Buy → Neutral
2015-09-09 Eingeleitet Raymond James Strong Buy
2015-05-12 Bestätigt UBS Buy
2015-04-08 Eingeleitet H.C. Wainwright Buy
2015-01-23 Bestätigt ROTH Capital Buy
2014-07-08 Fortgesetzt Oppenheimer Perform
2014-02-11 Eingeleitet Mizuho Buy
Alle ansehen

Verastem Inc Aktie (VSTM) Neueste Nachrichten

pulisher
Jul 25, 2025

What drives Verastem Inc. stock priceUnstoppable profit momentum - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer - Targeted Oncology

Jul 25, 2025
pulisher
Jul 25, 2025

Verastem Inc. Stock Analysis and ForecastRapid capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Verastem Inc. stockFree Market Dynamics Reports - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Is Verastem Inc. a good long term investmentAccelerated earnings growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha

Jul 24, 2025
pulisher
Jul 24, 2025

Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma

Jul 24, 2025
pulisher
Jul 24, 2025

FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada

Jul 24, 2025
pulisher
Jul 24, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve

Jul 23, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga

Jul 23, 2025
pulisher
Jul 22, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance

Jul 11, 2025

Finanzdaten der Verastem Inc-Aktie (VSTM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Verastem Inc-Aktie (VSTM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Calkins Daniel
Chief Financial Officer
Jun 20 '25
Sale
5.13
4,110
21,084
109,945
Calkins Daniel
Chief Financial Officer
Jun 23 '25
Sale
4.71
25
118
109,920
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):